Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Access the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food-effect of FCN-207 in Healthy Volunteers

NCT04622124 is registered in ClinicalTrials.gov with Fochon Pharmaceuticals, Ltd. as lead sponsor.

NCT NCT04622124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04622124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Access the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food-effect of FCN-207 in Healthy Volunteers
Lead sponsor
Fochon Pharmaceuticals, Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 11, 2020
Completion date
June 7, 2022
Enrollment
132 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperuricemia